Co-DiagnosticsHAM:C970 60 Days Payable is 909.78 as of Mar. 2026, which is 260% above its 10-year median of 252.57. GuruFocus rates HAM:C970 with a GF Score™ of 60/100 and a GF Value™ of €3.88. The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Co-Diagnostics ranks better than 96.48% on this metric.
The historical rank and industry rank for Co-Diagnostics's Days Payable or its related term are showing as below:
HAM:C970'
s Days Payable Range Over the Past 10 Years
Min: 6.64 Med: 252.57 Max: 26645
Current: 1797.58
During the past 11 years, Co-Diagnostics's highest Days Payable was 26645.00. The lowest was 6.64. And the median was 252.57.
HAM:C970's Days Payable is ranked better than 96.48% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs HAM:C970: 1797.58
Co-Diagnostics's Days Payable
declined
from Mar. 2025 (13,581.84) to Mar. 2026 (909.78).
It may suggest that Co-Diagnosticsaccelerated paying its suppliers.
Co-Diagnostics Days Payable Related Terms
Co-Diagnostics Days Payable Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:C970 vs ALRTF, SINT, HSCS: Days Payable Comparison
For the Medical Devices subindustry, Co-Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Co-Diagnostics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (HAM:C970) has a Days Payable of 909.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Co-Diagnostics and its competitors. This is 260% above median its historical median of 252.57. Over the past decade, Co-Diagnostics' Days Payable has ranged from 6.64 to 26,645.00. According to the industry distribution chart, Co-Diagnostics ranks #28 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 3.5%.
Is Co-Diagnostics' Days Payable too high?
Co-Diagnostics' current Days Payable of 909.78 is 260% above median its 10-year median of 252.57. Over the past 10 years, this metric has ranged from a low of 6.64 to a high of 26,645.00. The Medical Devices & Instruments industry median Days Payable is 68.07. Co-Diagnostics' value of 909.78 is 1236.5% above this industry median. Based on the distribution chart, Co-Diagnostics ranks #28 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Co-Diagnostics has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Days Payable compare to ALRTF and SINT?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #28 out of 795 companies for Days Payable. This places Co-Diagnostics in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Co-Diagnostics' value of 909.78 is 1236.5% above this benchmark. Historically, Co-Diagnostics' own Days Payable has ranged from 6.64 to 26,645.00 over the past decade. While the company's 10-year median is 252.57 vs. the industry median of 68.07, Co-Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Co-Diagnostics's current Days Payable of 909.78 is 1236.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current Days Payable is 909.78, which is 260% above median its own 10-year median of 252.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Days Payable of 909.78. The stock's GF Value™ is €3.88, compared to a current price of €5.55 — trading 43% above its estimated fair value. The current Days Payable is 909.78, which is 260% above median its 10-year median of 252.57 and 1236.5% above the Medical Devices & Instruments industry median of 68.07. Co-Diagnostics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Days Payable is 909.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 43% above its estimated GF Value™ of €3.88.
Key valuation signals for HAM:C970:
Days Payable: 909.78 (260% above median its 10-year median of 252.57)
GF Value™: €3.88 vs. price of €5.55 (43% above fair value)
Industry Position: 1236.5% above the Medical Devices & Instruments median (#28 of 795)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
60GF Score
Get the complete analysis for HAM:C970
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
